跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 12 天前AI 评分26

Microbot Medical 获得加拿大手术机器人器械适配器专利

8-K - Microbot Medical Inc. (0000883975) (Filer)

AI 导读

Microbot Medical 表示,加拿大知识产权局已授予其一项专利,涉及将细长手术工具近端连接至电动机器人手术设备的适配器,工具包括导丝和微导管。截至 11 月 5 日,公司在全球持有 45 项已授权专利和 48 项专利申请,其中北美有 21 项已授权专利。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2026

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware   000-19871   94-3078125

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 par value   MBOT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

Item 7.01. Regulation FD Disclosure.

On November 5, 2026, Microbot Medical Inc. (the “Company”) disseminated a press release announcing that the Canadian Intellectual Property Office (CIPO) granted the Company a patent for an adaptor for coupling a proximal portion of an elongate surgical tool (guidewire, microcatheter and the like) to a motorized robotic surgical device. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. By furnishing the information in this Current Report on Form 8-K and Exhibit 99.1, the Company is making no admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 8.01. Other Events.

As of November 5, 2026, the Company holds 45 issued patents and 48 patent applications worldwide, including 21 issued patents in North America.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

  Description
     
99.1   Press Release of Microbot Medical Inc., dated November 5, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  MICROBOT MEDICAL INC.
   
  By: /s/ Harel Gadot
  Name: Harel Gadot
  Title: Chief Executive Officer, President and Chairman

Date: November 5, 2026

 

来源:SEC EDGAR · 本站存档